Literature DB >> 32452124

Outcomes of recurrent nasopharyngeal carcinoma patients treated with endoscopic nasopharyngectomy: a meta-analysis.

Jingyi Yang1, Xiaole Song1, Xicai Sun1, Quan Liu1, Li Hu2, Hongmeng Yu1, Dehui Wang1.   

Abstract

BACKGROUND: Recurrent nasopharyngeal carcinoma (rNPC) is mainly managed with re-irradiation or salvage surgery. Endoscopic resection is generally considered as the preferred surgical treatment, whereas a standard treatment modality has yet to be established. This article is aimed to summarize the treatment outcomes of endoscopic rNPC resection.
METHODS: Major medical databases including PubMed, EMBASE, Cochrane Central Library, Web of Science, and 2 major Chinese databases, CNKI and Wanfang, were searched for studies on endoscopic rNPC resection. Main characteristics of study and outcomes of interest were retrieved from articles meeting the selection criteria for meta-analysis.
RESULTS: A total of 761 articles were identified through the initial systematic research. The combined 1-year, 2-year, and 5-year overall survival (OS) rates were 97%, 92%, and 73% with random effect model, respectively. The combined 2-year and 5-year disease-free survival (DFS) rates were 81% and 62%, respectively. Meta-regression analysis showed that high recurrent tumor (rT) stage (rT3 to rT4) case proportion was a correlative factor of heterogeneity. Combined 2-year OS rate in rT1, rT2, rT3, and rT4 patients were 100%, 87%, 78%, and 38%, respectively. Combined 2-year DFS rate in rT1 and rT2 patients were and 96% and 86%, respectively.
CONCLUSION: The combined OS and DFS rates of rNPC patients treated with endoscopic nasopharyngectomy were summarized and reported in our study. This meta-analysis indicated that endoscopic nasopharyngectomy has comparable and possibly better treatment outcomes than intensity-modulated radiotherapy (IMRT). Therefore, the result of our study indicated that randomized controlled trials (RCTs) are needed in rNPC patients to compare treatment outcomes of endoscopic nasopharyngectomy vs IMRT.
© 2020 ARS-AAOA, LLC.

Entities:  

Keywords:  endoscopic nasopharyngectomy; endoscopic skull-base surgery; meta-analysis; nasopharyngeal carcinoma; outcomes; recurrent nasopharyngeal carcinoma

Year:  2020        PMID: 32452124     DOI: 10.1002/alr.22552

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  5 in total

Review 1.  Recurrent Nasopharyngeal Cancer: Critical Review of Local Treatment Options Including Recommendations during the COVID-19 Pandemic.

Authors:  Michaela Svajdova; Marian Sicak; Pavol Dubinsky; Marek Slavik; Pavel Slampa; Tomas Kazda
Journal:  Cancers (Basel)       Date:  2020-11-25       Impact factor: 6.639

2.  Comparing the Effectiveness of Endoscopic Surgeries With Intensity-Modulated Radiotherapy for Recurrent rT3 and rT4 Nasopharyngeal Carcinoma: A Meta-Analysis.

Authors:  Zhouying Peng; Yumin Wang; Yaxuan Wang; Ruohao Fan; Kelei Gao; Hua Zhang; Weihong Jiang
Journal:  Front Oncol       Date:  2021-07-26       Impact factor: 6.244

3.  A combined microinvasive trans-submandibular and nasendoscopy surgical approach to dissect recurrent or radiotherapy-insensitive nasopharyngeal carcinoma.

Authors:  Yanming Zhao; Jugao Fang; Qi Zhong; Luo Zhang; Chengsuo Wang; Jiamin Zhang; Jiaming Chen; Ling Feng; Shizhi He; Hongzhi Ma; Lizhen Hou; Meng Lian; Qian Shi; Xixi Shen; Yifan Yang; Ru Wang
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

Review 4.  Treatment of Recurrent Nasopharyngeal Carcinoma: A Sequential Challenge.

Authors:  Zhouying Peng; Yumin Wang; Ruohao Fan; Kelei Gao; Shumin Xie; Fengjun Wang; Junyi Zhang; Hua Zhang; Yuxiang He; Zhihai Xie; Weihong Jiang
Journal:  Cancers (Basel)       Date:  2022-08-25       Impact factor: 6.575

5.  Balloon Test Occlusion of Internal Carotid Artery in Recurrent Nasopharyngeal Carcinoma Before Endoscopic Nasopharyngectomy: A Single Center Experience.

Authors:  Renhao Yang; Hui Wu; Binghong Chen; Wenhua Sun; Xiang Hu; Tianwei Wang; Yubin Guo; Yongming Qiu; Jiong Dai
Journal:  Front Oncol       Date:  2021-07-06       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.